 LUND, Sweden, April 15, 2021 PRNewswire -- Alligator Bioscience Nasdaq Stockholm: ATORX today announced that it has entered into a joint research collaboration with MacroGenics, Inc. NASDAQ: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The research collaboration will lead to the expansion of Alligators proprietary patient specific immunotherapy Neo-X-PrimeTM by incorporating MacroGenics proprietary DART and TRIDENT multi-specific platforms against two undisclosed targets. 